Directions for optimizing the therapy of bronchial asthma and status asthmaticus based on cross-sectional analysis of real-world data (RWD) from National Health Fund (NFZ) and Social Insurance Institution (ZUS)

Objectives The aim is to analyse the health and systemic effects of effective therapy for bronchial asthma and status asthmaticus in Poland for the purpose of assessing the possibility of introducing a model of coordinated care for patients with bronchial asthma and analysing the limitations resulting from the introduction of a coordinated care model. Methods The analysis was carried out based on actual data from the National Health Fund (NFZ) from 2013-2023 in the scope of the medical problem of bronchial asthma, defined by the codes of the main diagnosis ICD-10: asthma J45 and status asthmaticus J46. Results After the introduction of the first medicinal products for financing under the drug program for asthma treatment in 2013, a decrease in the number of patients registered for hospital treatment was observed at the level of: -2.79%, including, negative dynamics are observed in AOS and POZ. This means better disease control in patients, this conclusion is confirmedy the stable and maintained similar level of the distribution of the number of patients, taking into account the mode of admission to the hospital. Conclusions The introduction of the drug program for the treatment of bronchial asthma and the financing of medicinal product reduces the number of hospitalizations. After the introduction of the drug program, the number of benefits provided for incapacity for work due to bronchial asthma and the number of medical certificates have remained at a constant level. The number of days of sickness absence due to bronchial asthma has decreased.